The decision follows the initial approval granted in September 2023, which covered patients aged five years and above.

In recent study, 23 percent of NHANES primary prevention cohort currently using lipid-lowering therapies versus 47 percent eligible under U.S. guidelines.

Do you have high cholesterol? You're not alone — millions of adults in the United States face this common but serious issue. High cholesterol increases the risk of heart disease, ...

Heart disease is often seen as a problem that only affects older adults, but more and more young people are being diagnosed ...

What to Know About Managing Familial Hypercholesterolemia — A multipronged approach is needed for these patients to achieve adequate cholesterol lowering ...

Cholesterol is a type of fat found in your blood, and while your body needs it to create healthy cells, having high cholesterol levels can increase your risk of heart disease ...

An experimental treatment called VERVE-102 lowers the amount of "bad" cholesterol in the blood of people with specific ...

Ultragenyx Pharmaceutical Inc. shares plunged 30% as UX143 trial raises efficacy doubts. Click for more on RARE and my ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company’s investigational RNA interference ...

Switching what’s on your plate might change your cholesterol faster than you think—here’s what the latest research and ...

Studies suggest that artichoke extract can help lower cholesterol and blood pressure, reduce liver inflammation, and aid with ...

The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.